Methods and consumer products for detecting a metabolite

Patent metadata

Field	Value
Publication number	US-12578322-B2
Application number	US-202018034779-A
Country	US
Kind code	B2
Filing date	Dec 7, 2020
Priority date	Dec 7, 2020
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of androstenediol, oxtenedioate, digydrouracil, heptanoylglutamine, pregnenetriol, sulfate, heptenoylglutamine, hexanoylglutamine, guanine, methylhexanoylglutamine, hexanoylglycine, hexenoylglycine, spermidine, diacetylspermine, acisoga and combinations thereof; and producing a metabolic profile for the metabolite.

First claim

What is claimed is:

1 . A method of assessing lower urinary tract symptoms in a subject, the method comprising:
testing a urine sample from the subject for androstenediol and at least two metabolites selected from the group consisting of octenedioate, dihydrouracil, heptanoylglutamine, pregnenetriol sulfate, heptenoylglutamine, hexanoylglutamine, guanine, methylhexanoylglutamine, hexanoylglycine, hexenoylglycine, spermidine, diacetylspermine, acisoga, and combinations thereof; wherein testing comprises exposing a consumer product selected from the group consisting of personal hygiene products, incontinence products, wipes, disposable bed liners, baby and adult diaper products, child training pants, feminine pads and napkins, disposable testing products, testing strips, testing pads, toilet products, and combinations thereof to the urine sample; and producing a metabolic profile for the androstenediol and at least two metabolites; and using the metabolic profile to assess whether the subject has a lower urinary tract symptom selected from the group consisting of overactive bladder, urinary urge incontinence, and combinations thereof.

2 . The method of claim 1 , wherein the method further comprises communicating the metabolic profile.

3 . The method of claim 1 , wherein testing comprises testing for at least four metabolites.

4 . The method of claim 1 , wherein the subject is a female subject.

5 . The method of claim 1 , wherein the urine sample is tested in a location selected from the group consisting of point of care, a home, a toilet, a urine sample cup, a urine sample container, a catheter, a testing laboratory, a pad, a liner, and combinations thereof.

6 . The method of claim 1 , wherein testing comprises exposing the consumer product comprising a sensor to the urine sample.

7 . The method of claim 1 , wherein testing comprises a method selected from the group consisting of identification, detection, quantification, analysis, correlation, and combinations thereof.

8 . The method of claim 1 , wherein testing comprises a technique selected from the group consisting of protein analysis, antibody detection, metabolomic analysis, lateral flow assays, and combinations thereof.

9 . A consumer product for use in assessing bladder health of a subject, the consumer product comprising:
a sensor configured to test a urine sample from the subject for androstenediol and at least two metabolites selected from the group consisting of octenedioate, dihydrouracil, heptanoylglutamine, pregnenetriol sulfate, heptenoylglutamine, hexanoylglutamine, guanine, methylhexanoylglutamine, hexanoylglycine, hexenoylglycine, spermidine, diacetylspermine, acisoga, and combinations thereof; wherein the consumer product is selected from the group consisting of personal hygiene products, incontinence products, wipes, disposable bed liners, baby and adult diaper products, child training pants, feminine pads and napkins, disposable testing products, testing strips, testing pads, toilet products, and combinations thereof; and wherein the consumer product comprises an indicator for the androstenediol and the at least two metabolites.

10 . The consumer product of claim 9 , wherein the consumer product produces a visible change in response to the androstenediol and at least two metabolites, wherein the visible change is selected from the group consisting of a color change, a shape change, a readout, a written message, an electronic display, a printed display, and combinations thereof.

Assignees

• Kimberly Clark Co

Inventors

• Doney Elizabeth M
• Engelbrecht Kathleen C
• Koenig David W
• Quirk Stephen
• Kosnicki Kassi

Classifications

• G01N2030/8813

  biological materials · CPC title

• G01N30/88 Primary

  Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 · CPC title

• G01N2030/8831

  involving peptides or proteins · CPC title

• G01N30/72

  Mass spectrometers {(mass spectrometers per se H01J49/00)} · CPC title

• G01N33/493 Primary

  urine · CPC title